Erasca ERAS beats Q4 earnings estimates but shares decline 269 amid broader market weakness Kyverna Therapeutics KYTX Stock Changing Trend 420 20260418 NPCE Neuropace Q4 earnings beat estimates by 48 percent yet shares fall 487 percent on concerns